Therefore, the assessment of the number of PFN1+CD326+ CTCs in the peripheral blood of HNSCC patients can determine the presence of lymph node metastases with a sensitivity of 85% and a specificity of 96%. This evidence concerns the gene PFN1 and metastatic malignant neoplasm in the lymph nodes.